摘要
目的:探讨人尿激肽原酶对高危非致残性缺血性脑血管病的临床疗效。方法:选择将2016年1月至2017年1月我院接受治疗的高危非致残性缺血性脑血管的患者100例,随机分为观察组和对照组,各50例,对照组采用阿司匹林、氯吡格雷抗血小板治疗,观察组在对照组基础上采用人尿激肽原酶治疗,分析两组患者新发缺血性卒中的发生率以及治疗前后凝血功能变化。结果:观察组患者新发缺血性卒中等的发生率显著低于对照组,P<0.05,观察组治疗前后的凝血酶原时间(PT)、纤维蛋白原(Fib)与活化部分凝血活酶时间(APTT)与对照组无显著差异,P>0.05,观察组在静滴人尿激肽原酶前后的舒张压与收缩压无显著差异,P>0.05。结论:对高危非致残性缺血性脑血管病患者在应用阿司匹林、氯吡格雷抗血小板治疗的基础上联用人尿激肽原酶治疗,能降低患者出现新发缺血性脑卒中的发病概率,不会影响患者的凝血功能与血压。
Objective： To investigate the clinical efficacy of Human Urinary Kallidinogenase in high-risk non-disabling ischenfic cere- brovascular diseases. Methods： Select from January 2016 to January 2017 in our hospital treated 100 cases of high-risk non-disabling is- chemic cerebrovascular patients were randomly divided into observation group and control group, each of 50 cases, the control group using aspirin and clopidogrel antiplatelet therapy, the observation group in the control group on the basis of the original enzyme treatment of hu- man urinary kallikrein, analysis of the incidence and before and after treatment of blood coagulation function in two groups of patients with new onset ischemic stroke. Results： Patients with new onset ischemic stroke incidence of moderate significantly lower than the control group, P 〈 0. 05, the observation group before and after treatment, the prothrombin time （ PT）, fibrinogen （Fib） and activated partial thromboplastin time （APTT） had no significant difference with control group, P 〉 0. 05 in the observation group, no significant relaxation differential pressure and systolic blood pressure before and after intravenous infusion of Human Urinary Kallidinogenase, P 〉 0. 05. Con- clusion： For high-risk non-disabling in patients with ischemic cerebrovascular disease caused by human urinary kallidinogenase in the treatment of combined application of aspirin and clopidogrel antiplatelet therapy, can reduce the incidence in patients with new onset is- chemic stroke, will not affect the blood coagulation function and blood pressure of patients.
出处
《中国药物评价》
2017年第4期272-274,共3页
Chinese Journal of Drug Evaluation
关键词
人尿激肽原酶
高危非致残性缺血性脑血管病
临床疗效
Human urinary kallidinogenase
High-risk Non-disabling Ischemic Cerebrovascular Events（HR-NICE）
Clinical Effect
